Combination Therapy With Sodium Dichloroacetate and Potassium-Sodium Citrate in Patients With Stage IV Pancreatic Cancer
Sodium dichloroacetate (DCA), which reverses the Warburg effect of cancer cells, contributes to the alkalinization of the tumor along with a mixture of potassium-sodium (K/Na) citrate hydrate. We retrospectively evaluated the effect of the combination therapy of these in patients with stage IV pancreatic cancer. A total of 135 patients from February 2019 to August 2026 were included in this study. Eligible patients were divided into four groups: group D (DCA alone every other day), group DC (both DCA and K/Na citrate every other day), group D/C (either DCA or K/Na citrate on alternating days), and group DX (DCA every other day with ivermectin and tamoxifen every third DCA treatment). Simple pairwise comparisons of the Kaplan-Meier survival curves using the log-rank test showed significant differences between the D and DC groups and between the DC and DX groups, whereas no significant differences were observed in the other pairwise comparisons. On the other hand, the multivariable time-dependent Cox regression analysis, which accounts for the time from diagnosis to the initiation of treatment, showed a significantly higher hazard in the D, D/C, and DX groups than in the DC group. These findings suggest a potential survival benefit associated with the combination of DCA and K/Na citrate.
Authors
- Hiromasa Kurosaki (ORCID: https://orcid.org/0000-0003-4295-6118)
- Ryumei H Ishiguro
- H. Terunuma
- Miyu Ishiguro
- Atsushi Toki
- Tatsuaki Ishiguro
Publication Details
- Journal
- Cureus
- Published
- 2026-11-16
- DOI
- https://doi.org/10.7759/cureus.119739
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00